Search  in | Advanced
   Print  

Government/Regulatory Affairs

 
IN THIS SECTION

RESOURCES
2009 Government Affairs Agenda 

Summary of  2010 HHS Appropriations Bill

Ask the FDA Transcripts

QUICK LINKS
Government/Advisory Meetings

Contact AABB Public Policy Department

Contact AABB Regulatory Affairs Department

Regulatory Documents: AABB Impact Analysis
 
This section includes information on federal legislative and regulatory issues affecting the transfusion medicine and cellular therapies communities. The latest activity and general information on the issue are available by clicking on a link below. Also within this section, analysis and related resources provide a more in-depth look at the subject matter and offer strategies for compliance.

Bar Code Rule*
Biologics License Applications
Biovigilance*
Blood and Blood Components
Blood Safety and Availability*
Chagas' Disease
Creutzfeldt-Jakob Disease
Disaster Planning*
Donor Eligibility
Donor Testing*
Hepatitis
HCT/Ps
HIV
Infectious Diseases*
Irradiation
ISBT 128*
National Cord Blood Program*
Pandemic Influenza*
Patient Safety*
Platelets
Prescription Drug Marketing Act
Reimbursement
Research
Tissue*
West Nile Virus
Uniform Donor History Questionnaires

* Coming soon.

Last modified on 12/17/2009 5:49:04 PM
What's New!
AABB Weekly Report - March 12, 2010
Details
National Hemovigilance Program Launches to Track Adverse Events Associated with Blood Transfusion
Details
AABB Statement on XMRV Task Force
Details
Updated Circular of Information for Cellular Therapy Products
Details
Association Bulletin #10-01 - Association Bulletin Listings
Details
Current U.S. Blood Supply is Adequate to Handle Demands Resulting from Earthquake in Haiti
Details
Emerging Infectious Disease Agents
Details
Study Highlights Implications Of Influenza Pandemics On Blood Supplies
Details
Cellular Therapies Subsections
Details
Association Bulletin #09-08 - ISBT 128 Conditional Accreditation Status
Details
AABB Launches Facebook Fan Page
Details